Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AstraZeneca

GlaxoSmithKline

Teva Pharmaceutical

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.

FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic

AbbVie

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

Amgen

Moderna

Pfizer

Regeneron Pharmaceuticals

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Some of Novo Nordisk's popular weight loss drug Wegovy is back in stock in the U.S. after months of limited supplies, according to an update on the Food and Drug Administration's website, though shortages are set to continue as booming demand for obesity drugs still vastly outstrips Big Pharma's ability to ramp up production.

Wegovy Is Available Again After Shortages, FDA Says—But Supplies Are Still Limited

Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.

Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

The U.S. Food and Drug Administration website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy is available after being in short supply, while three other doses remained in limited availability due to increased demand.

One dose of Novo Nordisk's Wegovy back in supply, FDA website shows

Eli Lilly

UnitedHealth Group

Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs that can help diabetes and obesity, two significant health concerns around the world.

Forget Nvidia, These Unstoppable Stocks Are Better Buys

Novo Nordisk's weight loss drug, Wegovy, has received FDA approval for reducing the risk of major cardiovascular adverse events. Wegovy demonstrated a 20% reduction in the risk of major cardiovascular adverse events and a 19% reduction in the risk of all-cause death in the SELECT trial. The approval extends Novo Nordisk's leadership position in the obesity market and makes Wegovy eligible for Medicare coverage.

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Europe's biggest company, the Danish weight loss drug kingpin Novo Nordisk (NYSE:NVO)'s upcoming results will be squarely focused on the uptake of the flagship Wegovy drug in the US. Analysts have warned that the company risks undershooting forecasts due to Wegovy's slow uptake.

Novo Nordisk hopes to prove Wegovy naysayers wrong

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.

Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why

Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.

Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.

A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.

US Senate committee investigates pricing of Novo's Ozempic and Wegovy

Intra-Cellular Therapies

Viking Therapeutics

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

3 Biotech Stocks With Skyrocketing Potential: April 2024

Merck

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024

Novo Nordisk A/S - Articles of Association, April 2024

Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each.

Novo Nordisk A/S – Reduction of the share capital

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?

The Wegovy and Ozempic maker continues to buy its own shares. It purchased more than 200,000 of them last week.

Why Novo Nordisk Topped the Market Today

NVO continues to be rated as a Buy, with the stock already charting an impressive +16.1% rally over the past three months, well outperforming the wider market at +4.8%. The management recently announced multiple expansions in its manufacturing/fill finish capacities, with the ongoing shortages still implying immense consumer demand. We believe that these capex will eventually be accretive to NVO's top/bottom lines, especially since the PFE CEO, Albert Bourla, has estimated an obesity market size of up $150B.

Novo Nordisk Remains The Better Buy After A Moderate Pullback

Altimmune

GoodRx Holdings

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Vertex Pharmaceuticals

Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.

2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever

Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Health Care Select Sector SPDR Fund

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.

News for Novo Nordisk Stock (NVO)